Safety and efficacy of bimatoprost solution 0.03% topical application in patients with chemotherapy-induced eyelash loss.
Safety and efficacy of bimatoprost solution 0.03% topical application in patients with chemotherapy-induced eyelash loss.
复制标题
DOI：
10.1038/jidsymp.2013.30
复制
发表时间：
2013-12-01
期刊：
影响因子：
--
通讯作者：
Ahluwalia, Gurpreet S
中科院分区：
文献类型：
--
作者：
Ahluwalia, Gurpreet S
很少有皮肤病况携带与由疾病状况如斑秃或作为细胞毒性药物治疗的结果的脱发一样多的焦虑和情绪困扰，化疗后比马前列素0.03%溶液是美国食品药品监督管理局批准的处方产品，适用于治疗睫毛下垂。该产品在一项双盲、随机和安慰剂对照研究中进行了研究，研究对象是因化疗而出现明显睫毛脱落或睫毛减退的患者。每日一次用0.03%比马前列素滴眼液治疗上眼睑边缘可更快地恢复睫毛生长和突出，而在溶剂对照受试者中观察到的恢复过程较慢。使用经验证的总体睫毛评估（GEA）量表测量的睫毛突出度在治疗6个月后显示出相对于安慰剂的统计学显著增加。还使用经验证的客观数字图像分析方法证明了疗效，以显示这些患者的睫毛长度、厚度/丰满度和暗度显著增加。发现比马前列素在1年治疗期间耐受性良好。
Few dermatologic conditions carry as much anxiety and emotional distress as hair loss resulting from a disease condition such as alopecia areata or as a result of cytotoxic drug treatment, e.g., after chemotherapy. Bimatoprost 0.03% solution is a Food and Drug Administration-approved prescription product indicated for the treatment of eyelash hypotrichosis. The product was investigated in a double-masked, randomized, and placebo-controlled study in patients who had significant eyelash loss or hypotrichosis as a result of chemotherapy. Once-daily treatment with bimatoprost ophthalmic solution 0.03% to the upper eyelid margin restored eyelash growth and prominence more quickly than the slower, natural course of recovery observed in the vehicle control subjects. The eyelash prominence measured using a validated Global Eyelash Assessment (GEA) scale demonstrated a statistically significant increase over placebo following 6 months of treatment. Efficacy was also demonstrated using a validated objective digital image analysis methodology to show significant increase in eyelash length, thickness/fullness, and darkness in these patients. Bimatoprost was found to be well tolerated over the 1-year treatment period.